Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

被引：59

作者：

Giles, FJ

Vose, JM

Do, KA

Johnson, MM

Manshouri, T

Bociek, G

Bierman, PJ

O'Brien, SM

Kantarjian, HM

Armitage, JO

Albitar, M

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Nebraska, Med Ctr, Hematol Oncol Sect, Dept Internal Med, Omaha, NE 68182 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[4] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 06期

关键词：

Hodgkin's; lymphoma; VEGF; bFGF; HGF; angiogenin; prognosis; survival;

D O I：

10.1016/j.leukres.2003.11.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HID. (C) 2004 Published by Elsevier Ltd.

引用

页码：595 / 604

页数：10

共 52 条

[41]

SHIMOYAMA S, 1962, CANCER RES, V56, P703

[42] ANGIOGENIN ABOLISHES CELL-FREE PROTEIN-SYNTHESIS BY SPECIFIC RIBONUCLEOLYTIC INACTIVATION OF 40S RIBOSOMES [J].